Dublin, July 4, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/sz7hsd/microfluidics)
has announced the addition of the "Microfluidics
Market Report 2013-2018: Materials, Pharmaceuticals, Drug Delivery
Devices & IVD" report to their offering.
The global microfluidics market is valued at an estimated $1.59 billion in 2013 and is expected to grow at a CAGR of 17.6% in the next five years. The high growth in this market can be attributed to the rising demand for POC devices, quick return on investments provided by microfluidics devices which helps in cost reduction, and miniaturization of microfluidic chips.
The market is categorized into materials, products, and application segments. This report studies market estimations and trends for the above mentioned segments in three industries, namely, pharmaceutical, in-vitro diagnostics, and drug delivery devices. Factors such as the difficulty in incorporating emerging microfluidic technologies into existing workflows, and the complex and time consuming regulatory standards are hampering the growth of this market.
The market is expected to witness a high growth in the drug delivery devices segment, as these devices offer effective solutions for enhanced drug delivery through inhaler nozzles, micropumps, and micro needles. The micropumps market within the drug delivery devices segment is estimated to grow at the highest CAGR from 2013 to 2018; enhanced applications such as precise fluid control in nano and micro liter range are driving the growth of this market.
According to industry experts, the number of patent applications for microfluidics technology has increased from approximately 300 per year to around 4,000 per year. This increase in patent filings not only indicates the rising adoption of microfluidics technology across several applications but also the future opportunities in the competitive environment to capitalize the technology. Significant breakthroughs in nucleic acid analysis such as Human Genome project (HGP), and enhanced efficacy in applications such as drug discovery and Point-of-Care diagnosis are resulting in new patent filings.
North America accounts for the largest share of the global market, followed by Europe. However, Asia is expected to grow at the highest CAGR during the study period. The growth in investments and lower labor and raw material costs in this region are some of the major factors that are having a positive impact on the growth of the microfluidics market in Asia; markets such as China, Japan, India, and South Korea are the potential markets for investors in the near future.
Major players in the market include Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Caliper Life Sciences (PerkinElmer) (U.S.), Cepheid (U.S.), DanaherCorporation (U.S.), Life Technologies Corporation (U.S.), and Roche Diagnostics (Germany). A majority of companies in this market are from the U.S.
For more information visithttp://www.researchandmarkets.com/research/sz7hsd/microfluidics